Drugs & Targets FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi October 30, 2020Vol.46 No.41
Drugs & Targets FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC October 30, 2020Vol.46 No.41
Drugs & Targets CPI-613 receives FDA orphan drug designation for soft tissue sarcoma October 30, 2020Vol.46 No.41
Drugs & Targets EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals. October 30, 2020Vol.46 No.41
Drugs & Targets StrataNGS genomic profiling receives Medicare coverage in patients with advanced solid tumors October 30, 2020Vol.46 No.41
Drugs & Targets FoundationOne Liquid CDx companion diagnostic receives FDA approval in indications for targeted therapies in ovarian, breast and NSCLC October 30, 2020Vol.46 No.41
Drugs & Targets Venclexta combination receives FDA approval for untreated AML October 23, 2020Vol.46 No.40
Drugs & Targets Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer October 23, 2020Vol.46 No.40
Drugs & Targets Keytruda receives FDA approvals in Hodgkin lymphoma indications October 16, 2020Vol.46 No.39
